Influential cancer group to add drug-cost data to its treatment advice

When a U.S. cancer patient is prescribed drugs by their doctors now, the financial consequences play out over the course of treatment. But amid a growing national debate over drug prices, an influential coalition of cancer treatment centers, the National Comprehensive Cancer Network, will provide patients with info on the relative costs of different treatments, so they and their doctors can make more informed decisions. More from FiercePharma

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.